VERISMO THERAPEUTICS
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.
VERISMO THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2020-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.verismotherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
215-989-4225
Total Funding:
40 M USD
Technology used in webpage:
Euro GoDaddy
Similar Organizations
Amber Therapeutics
Amber Therapeutics develops the next-generation of bioelectrical therapies.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Catalym
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Clarapath
We are a medical robotics company developing the SectionStar, a platform to mimic the human histotechnician.
Eyebiotech
Eyebiotech is a privately held ophthalmology biotechnology company.
Headspace Health
Headspace is a digital health platform that provides guided meditation sessions and mindfulness training.
JOGO Health
JOGO Health is a biotech company focused on digital therepeutics for neuromuscular conditions.
Q Bio
On a mission to build the first Clinical Digital Twin Platform and make it accessible to everyone
Rona Therapeutics
Rona Therapeutics is a RNA therapeutics platform enabling discovery and development of modular and programmable RNA medicines.
Current Employees Featured
Pavel Aprelev Director of Corporate Development @ Verismo Therapeutics
Director of Corporate Development
2020-01-01
Michael C. Milone Co-Founder, Co-Chairman of Scientific Advisory Board @ Verismo Therapeutics
Co-Founder, Co-Chairman of Scientific Advisory Board
Bryan Kim Co-Founder and CEO @ Verismo Therapeutics
Co-Founder and CEO
Laura Johnson Chief Scientific Officer @ Verismo Therapeutics
Chief Scientific Officer
2021-07-01
Donald L. Siegel Co-Founder, Co-Chairman of Scientific Advisory Board @ Verismo Therapeutics
Co-Founder, Co-Chairman of Scientific Advisory Board
Sara Weiss Senior Vice President of Clinical Operations @ Verismo Therapeutics
Senior Vice President of Clinical Operations
2023-05-01
Mala Talekar Vice President of Clinical Development @ Verismo Therapeutics
Vice President of Clinical Development
2023-07-01
Founder
Investors List
DongKoo Bio&Pharma
DongKoo Bio&Pharma investment in Seed Round - Verismo Therapeutics
Hong Leong Bank
Hong Leong Bank investment in Seed Round - Verismo Therapeutics
BRV Capital Management
BRV Capital Management investment in Seed Round - Verismo Therapeutics
Key Employee Changes
Official Site Inspections
http://www.verismotherapeutics.com Semrush global rank: 13.24 M Semrush visits lastest month: 78
- Host name: 245.105.62.166.host.secureserver.net
- IP address: 166.62.105.245
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
Verismotherapeutics.com lookup results from whois.tucows.com server:
- Domain created: 27th-Sep-2020
- Domain updated: 12th-Sep-2024
- Domain expires: 27th-Sep-2025 0 Years, 98 Days left
- Website age: 4 Years, 266 Days
- Registrar Domain ID: 2562346839_DOMAIN_COM-VRSN
- Registrar Url: http://www.tucows.com
- Registrar WHOIS Server: whois.tucows.com
- Registrar Abuse Contact Email: domainabuse@tucows.com
- Registrar Abuse Contact Phone: +1.4165350123
- Name server:
- DNS1.P08.NSONE.NET
- DNS2.P08.NSONE.NET
- DNS3.P08.NSONE.NET
- DNS4.P08.NSONE.NET
- NS01.SQUARESPACEDNS.COM
- NS02.SQUARESPACEDNS.COM
- NS03.SQUARESPACEDNS.COM
- NS04.SQUARESPACEDNS.COM
More informations about "Verismo Therapeutics"
Verismo Therapeutics - Crunchbase Company Profile
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T …See details»
verismotherapeutics.com Reviews: Is this site a scam or legit?
While some are self-explanatory concerning verismotherapeutics.com, let's dive deeper into the remaining ones. Proximity to Potentially Harmful Websites. This metric gauges the connection, …See details»
Verismo Therapeutics Company Profile | Management and
Company Name. Verismo Therapeutics. Main Industry. Research & Development, Business Services. Website. www.verismotherapeutics.comSee details»
Verismo Therapeutics - LinkedIn
Verismo Therapeutics, a clinical-stage biotechnology company developing the novel KIR-CAR platform for solid tumors and blood cancers, today announced a strategic investment from IFLI …See details»
VERISMO THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VERISMO THERAPEUTICS, INC. of Philadelphia, PA. Get the latest business insights from Dun & …See details»
Verismo Therapeutics - PitchBook
Verismo Therapeutics General Information Description. Developer of cancer therapeutics designed to improve persistence and efficacy against solid tumor models. The company …See details»
Verismo Therapeutics Company Overview, Contact Details
John.Doe@verismotherapeutics.com: 50%. First.Last@verismotherapeutics.com: John.Doe@verismotherapeutics.com: 50%. See more formats. Frequently Asked Questions …See details»
Verismo Therapeutics - Overview, News & Similar companies
Verismo Therapeutics contact info: Phone number: (215) 989-4225 Website: www.verismotherapeutics.com What does Verismo Therapeutics do? Verismo Therapeutics is …See details»
Verismo Therapeutics - Craft
Verismo Therapeutics is a company that develops a KIR-CAR platform for cancer treatment. Its technology is based on chimeric antigen receptors (CAR) T-cell therapy for solid tumors …See details»
Verismo Therapeutics - Contacts, Employees, Board Members, …
Verismo Therapeutics is a biotechnology company that develops CAR T cell therapy for the treatment of solid tumors.See details»
Verismo Therapeutics - Products, Competitors, Financials, …
Headquarters Location. 3675 Market Street Suite 200. Philadelphia, Pennsylvania, 19104, United States. 215-989-4225See details»
Verismo Therapeutics CEO and Key Executive Team | Craft.co
Verismo Therapeutics's Co-Founder and CEO/President is Bryan Kim. Other executives include Raymond Luke, Director of MSAT; Laura A Johnson, Chief Scientific Officer and 3 others. See …See details»
Team - Verismo Therapeutics: Defining a New Generation of KIR …
From Kymriah™ to SynKIR™ Verismo was founded by the inventors of Kymriah™, the first-ever FDA-approved CAR T cell therapy. This same team saw an opportunity to overcome the …See details»
Verismo Therapeutics Inc - Company Profile and News
Company profile page for Verismo Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Verismo Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Sep 7, 2023 Explore Verismo Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 27 news, Disease Domain:Neoplasms, Endocrinology and …See details»
Join Us - Verismo
Start Your Career With Verismo. Verismo is transforming the treatment of solid tumors using nature-inspired multichain receptors. If you’re looking for a rewarding career experience fueled …See details»
Verismo Therapeutics - VentureRadar
Similar Companies: GAIA BioMedicine Unknown Privately Held GAIA BioMedicine, Inc., founded in 2015 as a spin-off venture of Kyushu University, is a technology-driven biopharmaceutical …See details»
Verismo Therapeutics Completes Merger to Accelerate Clinical …
Dec 20, 2024 For more information, visit: www.verismotherapeutics.com. About HLB Group. The HLB Group is comprised of HLB Inc. (KOSDAQ:028300) and its affiliates with a diverse …See details»
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV …
Feb 28, 2023 Lead investor BRV Capital Management is joined by Ignite Innovation. PHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T …See details»
Verismo doses first subject in Phase I trial of SynKIR-310
4 hours ago Subjects will be divided into two cohorts, with each cohort consisting of three to six individuals. Credit: Volha_R/Shutterstock. Verismo Therapeutics has commenced the first …See details»